203 related articles for article (PubMed ID: 38101905)
1. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes.
Farina A; Villagrán-García M; Vogrig A; Zekeridou A; Muñiz-Castrillo S; Velasco R; Guidon AC; Joubert B; Honnorat J
Lancet Neurol; 2024 Jan; 23(1):81-94. PubMed ID: 38101905
[TBL] [Abstract][Full Text] [Related]
2. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes.
Blaes F
Expert Rev Neurother; 2021 Jun; 21(6):675-686. PubMed ID: 33960258
[No Abstract] [Full Text] [Related]
4. Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment.
Mongay-Ochoa N; Vogrig A; Muñiz-Castrillo S; Honnorat J
J Neurol; 2020 Jul; 267(7):2154-2156. PubMed ID: 32451614
[No Abstract] [Full Text] [Related]
5. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.
Valencia-Sanchez C; Zekeridou A
Front Neurol; 2021; 12():642800. PubMed ID: 33897597
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy.
Kang K; Zheng K; Zhang Y
J Immunother; 2020 Jun; 43(5):165-168. PubMed ID: 32195750
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review.
Kapagan T; Aksu F; Yuzkan S; Bulut N; Erdem GU
J Oncol Pharm Pract; 2024 Jan; 30(1):201-205. PubMed ID: 37321205
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic neurological syndromes in patients affected by SCLC: a case series.
Zanella C; Leone AG; Zambelli L; Bottiglieri A; Canziani L; Brambilla M; Lo Russo G; Platania M; De Braud F; Occhipinti M
Tumori; 2022 Dec; 108(6):NP11-NP14. PubMed ID: 35260015
[TBL] [Abstract][Full Text] [Related]
9. New concepts in paraneoplastic neurological syndromes.
Honnorat J; Viaccoz A
Rev Neurol (Paris); 2011 Oct; 167(10):729-36. PubMed ID: 21890156
[TBL] [Abstract][Full Text] [Related]
10. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.
Farina A; Birzu C; Elsensohn MH; Picca A; Muñiz-Castrillo S; Vogrig A; Villagrán-García M; Ciano-Petersen NL; Massacesi L; Hervier B; Guégan S; Kramkimel N; Vano Y; Salem JE; Allenbach Y; Maisonobe T; Assaad S; Maureille A; Devic P; Weiss N; Pegat A; Maucort-Boulch D; Ricard D; Honnorat J; Psimaras D; Joubert B
Brain Commun; 2023; 5(3):fcad169. PubMed ID: 37389303
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic neurological syndromes: clinical presentations and management.
Devine MF; Kothapalli N; Elkhooly M; Dubey D
Ther Adv Neurol Disord; 2021; 14():1756286420985323. PubMed ID: 33796141
[TBL] [Abstract][Full Text] [Related]
12. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.
Duong SL; Prüss H
Neurotherapeutics; 2022 Apr; 19(3):848-863. PubMed ID: 35043373
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects.
Storstein A; Vedeler CA
Adv Clin Chem; 2007; 44():143-85. PubMed ID: 17682342
[TBL] [Abstract][Full Text] [Related]
14. Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors.
Jean MJ; Samkoff L; Mohile N
Curr Treat Options Oncol; 2024 Jan; 25(1):42-65. PubMed ID: 38198120
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic Neurologic Disorders.
Gilligan M; McGuigan C; McKeon A
Curr Neurol Neurosci Rep; 2023 Mar; 23(3):67-82. PubMed ID: 36781586
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic neurological syndromes.
Leypoldt F; Wandinger KP
Clin Exp Immunol; 2014 Mar; 175(3):336-48. PubMed ID: 23937626
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.
Graus F; Dalmau J
Nat Rev Clin Oncol; 2019 Sep; 16(9):535-548. PubMed ID: 30867573
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic neurological syndrome: growing spectrum and relevance.
Ganaraja VH; Rezk M; Dubey D
Neurol Sci; 2022 Jun; 43(6):3583-3594. PubMed ID: 35460452
[TBL] [Abstract][Full Text] [Related]
20. [Paraneoplastic Disorders of the Central Nervous System].
Kimura A
Brain Nerve; 2021 May; 73(5):620-630. PubMed ID: 34006696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
